NovImmune inks deal, eyes possible IPO

Genentech has forged a licensing pact with Geneva-based NovImmune for an early-stage IL-17 antibody that may be useful in treating inflammatory and autoimmune diseases. And the Swiss biotech, which has raised SFR$154 million, says the deal may help advance plans for a possible IPO. Story